FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

92 letters match. Newest first.

  1. C&T Dream Co., Ltd.

    C&T Dream failed CGMP (current good manufacturing practice) for its over-the-counter Dry Skin Healing Ointment, including identity testing and process validation.

    High risk
  2. FirstCham Co., Ltd.

    FDA warns FirstCham over current good manufacturing practice violations and misbranding of Soo'Ae hand sanitizing wipes.

    High risk
  3. Betone S.A. de C.V.

    FDA warns Betone S.A. de C.V. over manufacturing violations for OTC antiseptic wipes, including subpotent active and missing glycerin safety tests.

    High risk
  4. Higley Industries, Inc.

    FDA warns Higley Industries over CGMP failures in OTC drug manufacturing, including untested ethanol and glycerin.

    High risk
  5. Cosmetic Specialty Labs, Inc.

    FDA warned Cosmetic Specialty Labs after an inspection found manufacturing failures in OTC drugs and an unlisted product.

    High risk
  6. Bell International Laboratories, Inc.

    Bell International Laboratories, an OTC drugmaker, was cited for manufacturing rule violations including missing glycerin DEG/EG testing and inadequate quality oversight.

    High risk
  7. Les Importations Herbasanté Inc.

    Canadian contract maker of homeopathic drugs, including children's products, skipped ingredient testing and process validation, FDA says.

    High risk
  8. Glicerinas Industriales, S.A. de C.V.

    FDA warned Glicerinas Industriales over CGMP failures in repackaged glycerin and propylene glycol, including DEG/EG testing and particulate contamination.

    High risk
  9. Prime Lab LLC

    Prime Lab LLC failed U.S. drug manufacturing quality rules for over-the-counter hand soaps and sanitizers, including raw-material testing and shared toxic equipment.

    High risk
  10. Woorilife & Health

    Woorilife & Health, a South Korean OTC drug maker, failed to test high-risk ingredients for DEG/EG and lacked quality-unit oversight.

    High risk
  11. Patcos Cosmetics Pvt. Ltd.

    Patcos Cosmetics, an Indian OTC drug maker, failed to test high-risk ingredients for DEG/EG and lacked quality-unit oversight.

    High risk
  12. Dextrum Laboratories Inc.

    FDA found Dextrum Laboratories, an over-the-counter drug contract manufacturer, failed identity testing, toxic glycol checks, water monitoring, and process validation.

    High risk
  13. AmLion Toothpaste Mfg. Sdn. Bhd.

    FDA cites AmLion Toothpaste in Malaysia for CGMP failures, including no testing of glycerin and sorbitol for DEG/EG; firm stays on import alert.

    High risk
  14. Global Pharma Healthcare Private Limited

    FDA warned Global Pharma Healthcare that non-sterile artificial tears and eye ointment from its India plant were tied to a Pseudomonas outbreak with four deaths.

    High risk
  15. Seoul Cosmetics Co., Ltd.

    FDA warned Seoul Cosmetics, a South Korean drug maker, over poor manufacturing quality and unapproved OTC drugs.

    High risk
  16. Zhao Qing Longda Biotechnology Co. Ltd.

    FDA says Zhao Qing Longda Biotechnology refused records access for OTC drugs, including children’s toothpaste, and placed its drugs on import alert.

    High risk
  17. Lex Inc.

    FDA warns Lex Inc. of Medley, Florida, that its over-the-counter drugs are adulterated because manufacturing rules were not met, including missing toxic-ingredient testing.

    High risk
  18. K. Boeun Pharmaceutical Co., Ltd.

    K. Boeun Pharmaceutical's OTC drugs were cited for CGMP violations, including missing identity tests for DEG/EG-risk components and inadequate quality unit.

    High risk
  19. Denison Pharmaceuticals, LLC

    Denison Pharmaceuticals was cited for manufacturing quality failures, contamination risks, and unapproved infant/homeopathic drugs.

    High risk
  20. Avaria Health & Beauty Corp.

    FDA cites Avaria Health & Beauty for manufacturing-rule violations in OTC drugs, including missing glycerin identity testing and weak quality unit.

    High risk
  21. Tan Alize Kozmetik Ve Temizlik Urunleri

    FDA warns Turkish OTC drug maker Tan Alize over missing glycerin identity testing and a weak quality unit; import alert issued.

    High risk
  22. Sangleaf Pharm., Co. Ltd.

    Sangleaf Pharm failed to give FDA requested records for OTC drugs, including children's toothpaste, at risk of DEG/EG contamination.

    High risk
  23. LCC Ltd.

    LCC Ltd., an OTC drug maker, lacked identity testing for risky ingredients and adequate quality oversight, FDA says.

    High risk
  24. Suhan Aerosol

    Suhan Aerosol, an Indian OTC drug maker, failed to test high-risk ingredients for toxic diethylene/ethylene glycol and lacked quality oversight.

    High risk
  25. Skyline Herbals Private Limited

    FDA warns India's Skyline Herbals after it ignored records requests for OTC drugs including toothpaste; all its drugs hit Import Alert 66-79.

    High risk
  26. Daxal Cosmetics Private Limited

    FDA warns Daxal Cosmetics for refusing records on over-the-counter drugs, including toothpaste, at risk for diethylene glycol and ethylene glycol contamination.

    High risk
  27. Orchid Lifesciences

    FDA warns Orchid Lifesciences over over-the-counter drug testing gaps and weak quality unit.

    High risk
  28. Medgel Private Limited

    FDA cited Medgel Private Limited, an Indian OTC drug maker, for manufacturing violations including poor investigations and data integrity failures.

    High risk
  29. Avlon Industries, Inc.

    FDA warned Avlon Industries that its over-the-counter drug manufacturing broke quality rules, citing missing identity tests for high-risk glycerin/propylene glycol and validation failures.

    High risk
  30. Fuller Industries Inc.

    FDA warns Fuller Industries over current good manufacturing practice violations in OTC hand soaps and sanitizers, including quality oversight and ingredient testing.

    High risk
  31. NeilMed Pharmaceuticals Inc.

    FDA warned NeilMed Pharmaceuticals that its OTC drug manufacturing had current good manufacturing practice violations, including missing glycerin identity testing and dirty equipment.

    High risk
  32. Accra-Pac, Inc. dba Voyant Beauty

    Voyant Beauty's Elkhart, Indiana plant made OTC aerosol drugs contaminated with benzene and failed to investigate or test properly.

    High risk
  33. Pharmaplast S.A.E.

    FDA cited Pharmaplast S.A.E. for failing to test drug components, including glycerin and ethanol, for dangerous contaminants.

    High risk
  34. Champaklal Maganlal Homeo Pharmacy Private Limited

    Champaklal Maganlal Homeo Pharmacy failed to test each glycerin lot for identity, including DEG/EG, in OTC and homeopathic drugs.

    High risk
  35. Omega Packaging Corp

    Omega Packaging Corp failed to test hand sanitizer ingredients and validate processes, FDA found.

    High risk
  36. Dunagin Pharmaceuticals Inc. dba Massco Dental

    Dunagin Pharmaceuticals dba Massco Dental made oral drugs with CGMP violations including shared equipment and inadequate component testing.

    High risk
  37. Profounda, Inc.

    FDA warns Profounda about manufacturing quality failures for over-the-counter drugs, including process validation, stability, water system, and glycerin testing.

    High risk
  38. AG Hair Limited

    FDA warned AG Hair Limited over CGMP failures for hand sanitizer drugs, including inadequate investigations, microbiological controls, and component testing.

    High risk
  39. Glicerinas Industriales, S.A. de C.V.

    Glicerinas Industriales refused a pre-announced FDA inspection; FDA calls its glycerin drugs adulterated and placed firm on Import Alert 66-79.

    High risk
  40. Aire-Master of America, Inc.

    FDA cites Aire-Master of America for CGMP failures and unapproved, misbranded hand sanitizers made at its Missouri plant.

    High risk
  41. Froggy’s Fog LLC

    FDA warns Froggy’s Fog that its OTC hand sanitizer was made under inadequate CGMP and mislabeled for alcohol strength.

    High risk
  42. Professional Compounding Centers of America dba PCCA

    PCCA received adulterated drug ingredients from suppliers on FDA import alerts and failed adequate glycerin identity testing.

    High risk